Axoltis pharma is a biopharmaceutical company dedicated to develop drugs for neurological disorders.
Its vocation is to develop first-in-class disease-modifying drugs to treat patients with neurodegenerative or traumatic disorders with high unmet medical needs.
http://www.axoltis.com
“BCIP Consulting has helped us having a clear understanding of the status of our exclusivity potential. Starting from this initial diagnostic, BCIP consulting has worked with us to sharpen our IP strategy going forward.” Yann Godfrin, CEO Axoltis pharma